Ghrelin and growth hormone secretagogues, physiological and pharmacological aspect

Current Drug Discovery Technologies

Volumn 6, Issue 1, 2009, Pages 34-42

  Cordido, Fernando ^a,b,c   Isidro, Maria Luisa ^a   Nemiña, Rosa ^a   Sangiao Alvarellos, Susana ^a,b  

^a Hospital Juan Canalejo A Coruña   (Spain)

^b UNIVERSITY OF A CORUÑA   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Ghrelin; Growth hormone secretagogues

Indexed keywords

CORTICOTROPIN; GHRELIN; GHRELIN RECEPTOR; GLUCOSE; GROWTH HORMONE DERIVATIVE; HEXARELIN; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; PRALMORELIN; PROLACTIN;

DRUG MECHANISM; ENERGY BALANCE; GASTROINTESTINAL MOTILITY; GLUCOSE METABOLISM; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-OBESITY AGENTS; GHRELIN; GROWTH HORMONE; HUMANS; OBESITY; RECEPTORS, GHRELIN;

EID: 62149141741     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016309787581048     Document Type: Review

References (109)

1. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K.: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402(6762), 656, (1999).
2. Tschop M., Smiley D.L., Heiman M.L.: Ghrelin induces adiposity in rodents. Nature 407(6806), 908, (2000).
3. Ghigo E., Arvat E., Giordano R., Broglio F., Gianotti L., Maccario M., Bisi G., Graziani A. et al.: Biologic activities of growth hormone secretagogues in humans. Endocrine 14(1), 87, (2001).
4. Bowers C.Y., Chang J., Momany F.A., Folkers K.: Effect of enkephalins and enkephalins analogs on release of pituitary hormones in vitro, Molecular Endocrinology, Ed.; Elservier: MacIntyre G, Szelke H, Amsterdam, pp. 287-292, (1977).
5. Casanueva F.F., Dieguez C.: Growth Hormone Secretagogues: Physiological Role and Clinical Utility. Trends Endocrinol. Metab. 10(1), 30, (1999).
6. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., Hamelin M., Hreniuk D.L. et al.: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273(5277), 974, (1996).
7. van der Lely A., Tschöp M., Heiman M., Ghigo E.: Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 25(3), 426, (2004).
8. Date Y., Kojima M., Hosoda H., Sawaguchi A., Mondal M.S., Suganuma T., Matsukura S., Kangawa K. et al.: Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tract of rats and humans. Endocrinology 141(11), 4255, (2000).
9. Fukushima N., Hanada R., Teranishi H., Fukue Y., Tachibana T., Ishikawa H., Takeda S., Takeuchi Y. et al.: Ghrelin directly regulates bone formation. J. Bone Miner. Res. 20(5), 790, (2006).
10. Muccioli G., Tschöp M., Papotti M., Deghenghi R., Heiman M., Ghigo E.: Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur. J. Pharmacol. 440(2-3), 235, (2002).
11. Kojima M., Kangawa K.: Ghrelin: structure and function. Physiol. Rev. 85 (2), 495, (2005).
12. Gauna C., Meyler F.M., Janssen J.A., Delhanty P.J., Abribat T., van Koetsveld P., Hofland L.J., Broglio F. et al.: Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J. Clin. Endocrinol. Metab. 89(10), 5035, (2004).
13. Zhang J.V., Ren P.G., Avsian-Kretchmer O., Luo C.W., Rauch R., Klein C., Hsueh A.J.: Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310(5750), 996, (2005).
14. Nogueiras R., Pfluger P., Tovar S., Arnold M., Mitchell S., Morris A., Perez-Tilve D., Vázquez M.J. et al.: Effects of obestatin on energy balance and growth hormone secretion in rodents. Endocrinology 148(1), 21, (2007).
15. Holst B., Egerod K.L., Schild E., Vickers S.P., Cheetham S., Gerlach L.O., Storjohann L., Stidsen C.E. et al.: GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 148(1), 13, (2007).
16. Chartrel N., Alvear-Perez R., Leprince J., Iturrioz X., Reaux-Le Goazigo A., Audinot V., Chomarat P., Coge F. et al.: Comment on "Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake". Science 315(5813), 766, (2007).
17. Samson W.K., White M.M., Price C., Ferguson A.V.: Obestatin acts in brain to inhibit thirst. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292(1), R637, (2007).
18. Guo Z.F., Zheng X., Qin Y.W., Hu J.Q., Chen S.P., Zhang Z.: Circulating preprandial ghrelin to obestatin ratio is increased in human obesity. J. Clin. Endocrinol. Metab. 92(5),1875, (2007).
19. Cummings D.E., Purnell J.Q., Frayo R.S., Schmidova K., Wisse B.E., Weigle D.S.: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50(8), 1714, (2001).
20. Cummings D.E., Weigle D.S., Frayo R.S., Breen P.A., Ma M.K., Dellinger E.P., Purnell J.Q.: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. 346(21), 1623, (2002).
21. Shiiya T., Nakazato M., Mizuta M., Date Y., Mondal M.S., Tanaka M., Nozoe S., Hosoda H. et al.: Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J. Clin. Endocrinol. Metab. 87(1), 240, (2002).
22. Callahan H.S., Cummings D.E., Pepe M.S., Breen P.A., Matthys C.C., Weigle D.S.: Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J. Clin. Endocrinol. Metab. 89(3), 1319, (2004).
23. Erdmann J., Lippl F., Schusdziarra V.: Differential effect of protein and fat on plasma ghrelin levels in man. Regul. Pept. 116(1-3), 101, (2003).
24. Al Awar R., Obeid O., Hwalla N., Azar S.: Postprandial acylated ghrelin status following fat and protein manipulation of meals in healthy young women. Clin. Sci. (Lond) 109(4), 405, (2005).
25. Greenman Y, Golani N, Gilad S, Yaron M, Limon R, Stern N: Ghrelin secretion is modulated in a nutrient- and gender-specific manner. Clin. Endocrinol. 60(3), 382, (2004).
26. le Roux C.W., Patterson M., Vincent R.P., Hunt C, Ghatei M.A., Bloom S.R.: Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J. Clin. Endocrinol. Metab. 90(2), 1068, (2005).
27. Arosio M, Ronchi CL, Beck-Peccoz P, Gebbia C, Giavoli C, Cappiello V, Conte D, Peracchi M: Effects of modified sham feeding on ghrelin levels in healthy human subjects. J. Clin. Endocrinol. Metab. 89(10), 5101, (2004).
28. Perez-Fontan M., Cordido F., Rodriguez-Carmona A., Garcia-Naveiro R., Isidro M.L., Villaverde P., Garcia-Buela J.: Acute plasma ghrelin and leptin responses to oral feeding or intraperitoneal hypertonic glucose-based dialysate in patients with chronic renal failure. Kidney Int. 68(6), 2877, (2005).
29. Pérez-Fontán M., Cordido F., Rodríguez-Carmona A., Penín M., Díaz-Cambre H., López-Muñiz A., Sangiao-Alvarellos S., García-Buela J: Shortterm regulation of peptide YY secretion by a mixed meal or peritoneal glucose-based dialysate in patients with chronic renal failure. Nephrol. Dial. Transplant. 23(11), 3696, (2008).
30. Blom W.A., Stafleu A., de Graaf C., Kok F.J., Schaafsma G., Hendriks H.F.: Ghrelin response to carbohydrate-enriched breakfast is related to insulin. Am. J. Clin. Nutr. 81(2), 367, (2005).
31. Purnell J.Q., Weigle D.S., Breen P., Cummings D.E.: Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J. Clin. Endocrinol. Metab. 88(12), 5747, (2003).
32. Schaller G., Schmidt A., Pleiner J., Woloszczuk W., Woltzt M., Luger A.: Plasma ghrelin concentrations are not regulated by glucose or insulin: a double-blind, placebo-controlled crossover clamp study. Diabetes 52(1), 16, (2003).
33. Caixas A., Bashore C., Nash W., Pi-Sunyer X., Laferrere B. Insulin, unlike food intake, does not suppress ghrelin in human subjects. J. Clin. Endocrinol. Metab. 87(4), 1902, (2002).
34. Haqq A.M., Farooqi I.S., O'Rahilly S., Stadler D.D., Rosenfeld R.G., Pratt K.L., LaFranchi S.H., Purnell J.Q.: Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab 88(1), 174, (2003).
35. Otto B., Cuntz U., Fruehauf E., Wawarta R., Folwaczny C., Riepl R.L., Heiman M.L., Lehnert P. et al.: Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur. J. Endocrinol. 145(5), 669, (2001).
36. Ukkola O.: Ghrelin and insulin metabolism. Eur. J. Clin. Invest. 33(3), 183, (2003).
37. McLaughlin T., Abbasi F., Lamendola C., Frayo R.S., Cummings D.: Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J. Clin. Endocrinol. Metab. 89(4), 1630, (2004).
38. Barazzoni R., Zanetti M., Ferreira C., Vinci P., Pirulli A., Mucci M., Dore F., Fonda M. et al.: Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 92(10), 3935, (2007).
39. Tschöp M., Weyer C., Tataranni P.A., Devanarayan V., Ravussin E., Heiman M.L.: Circulating ghrelin levels are decreased in human obesity. Diabetes 50(4), 707, (2001).
40. Tritos N.A., Kokkotou E.G.: The physiology and potential clinical applications of ghrelin, a novel peptide hormone. Mayo Clin. Proc. 81(5), 653, (2006).
41. Norrelund H., Hansen T.K., Orskov H., Hosoda H., Kojima M., Kangawa K., Weeke J., Moller N., Christiansen J.S., Jorgensen J.O.: Ghrelin immunoreactivity in human plasma is suppressed by somatostatin. Clin. Endocrinol. (Oxf) 57 (4), 539, (2002).
42. Barkan A.L., Dimakari E.V., Jessup S.K., Symons K.V., Ermolenko M., Jaffe C.: Ghrelin Secretion in Humans Is Sexually Dimorphic, Suppressed by Somatostatin, and Not Affected by the Ambient Growth Hormone Levels. J. Clin. Endocrinol. Metab. 88(5), 2180, (2003).
43. Cordido F., Peñalva A., Dieguez C., Casanueva F.F.: Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J. Clin. Endocrinol. Metab. 76(4), 819, (1993).
44. Alvarez P., Isidro L., Garcia-Buela J., Leal-Cerro A., Broglio F., Tassone F., Ghigo E., Dieguez C. et al.: Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients. Clin. Endocrinol. 61(2), 250, (2004).
45. Edén Engström B., Burman P., Holdstock C., Karlsson F.A.: Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. J. Clin. Endocrinol. Metab. 88(11), 5193, (2003).
46. Espelund U., Hansen T.K., Højlund K., Beck-Nielsen H., Clausen J.T., Hansen B.S., Orskov H., Jørgensen J.O. et al.: Fasting unmasks a strong inverse association between ghrelin and cortisol in serum: studies in obese and normal-weight subjects. J. Clin. Endocrinol. Metab. 90(2), 741, (2005).
47. Freda P.U., Reyes C.M., Conwell I.M., Sundeen R.E., Wardlaw S.L.: Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy. J. Clin. Endocrinol. Metab. 88(5), 2037, (2003).
48. Giménez-Palop O., Giménez-Pérez G., Mauricio D., Berlanga E., Potau N., Vilardell C., Arroyo J., González-Clemente J.M. et al.: Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes. Eur. J. Endocrinol. 153(1), 73, (2005).
49. Mackelvie K.J., Meneilly G.S., Elahi D., Wong A.C., Barr S.I., Chanoine J.P.: Regulation of appetite in lean and obese adolescents after exercise: role of acylated and desacyl ghrelin. J. Clin. Endocrinol. Metab. 92(2), 648, (2007).
50. Broglio F., Benso A., Gottero C., Prodam F., Gauna C., Filtri L., Arvat E. van der Lely A.J. et al.: Non-acylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans. J. Endocrinol. Invest. 26(3), 192, (2003).
51. Arvat E., Macario M., Di Vito L., Broglio F., Benso A., Gotero C., Papotti M., Muccioli G. et al.: Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interaction with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormene. J. Clin. Endocrinol. Metab. 86(3), 1169, (2001).
52. Sun Y., Ahmed S., Smith R.G.: Deletion of ghrelin impairs neither growth nor appetite. Mol. Cell Biol. 23(22), 7973, (2003).
53. Pantel J., Legendre M., Cabrol S., Hilal L., Hajaji Y., Morisset S., Nivot S., Vie-Luton M.P. et al.: Loss of constitutive activity of the growth hormone secretagogue receptor in famlial short stature. J. Clin. Invest. 116(3), 760, (2006).
54. Popovic V., Leal A., Micic D., Koppeschaar H.P., Torres E., Páramo C., Obradovic C., Dieguez C. et al.: GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet 356(9236), 1137, (2000).
55. Baldelli R., Otero X.L., Camina J.P., Gualillo O., Popovic V., Dieguez C., Casanueva, F.F.: Growth hormone secretagogues as diagnostic tools in disease states. Endocrine 14(1), 95, (2001).
56. Cordido F., Alvarez-Castro P., Isidro L., Casanueva F., Dieguez C.: Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients. Eur. J. Endocrinol. 149(2), 117, (2003).
57. Aimaretti G., Baffoni C., Broglio F., Janssen J.A., Corneli G., Deghenghi R., van der Lely A.J., Ghigo E. et al.: Endocrine responses to ghrelin in adult patients with isolated childhood-onset growth hormone deficiency. Clin. Endocrinol. 56(6), 765, (2002).
58. Popovic V., Pekic S., Golubic I., Doknic M., Dieguez C., Casanueva F.F.: The impact of cranial irradiation on GH responsiveness To GHRH plus GHRP-6. J. Clin. Endocrinol. Metab. 87(5), 2095, (2002).
59. Maccario M., Veldhuis J.D., Broglio F., Vito L.D., Arvat E., Deghenghi R., Ghigo E.: Impact of two or three daily subcutaneous injections of hexarelin, a synthtic growth hormone secretagogue, on 24 h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. Eur. J. Endocrinol. 146(2), 310, (2002).
60. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., Matsukura S.: A role for Ghrelin in the central regulation of feeding. Nature 409(6817), 194, (2001).
61. Wren A.M., Seal L.J., Cohen M.A., Brynes A.E., Frost G.S., Murphy K.G., Dhillo W.S., Ghatei M.A. et al.: Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86(12), 5992, (2001).
62. Drazen D.L., Woods S.C.: Peripheral signals in the control of satiety and hunger. Curr. Opin. Clin. Nutr. Metab. Care 6(6), 621, (2003).
63. Wortley K.E., del Rincon J.P., Murray J.D., Garcia K., Iida K., Thorner M.O., Sleeman M.W.: Absence of ghrelin protects against early-onset obesity. J. Clin. Invest. 115(12), 3573, (2005).
64. Giménez-Palop O., Giménez-Pérez G., Mauricio D., González-Clemente J.M., Potau N., Berlanga E., Trallero R., Laferrère B. et al.: A lesser postprandial suppression of plasma ghrelin in Prader-Willi syndrome is associated with low fasting and a blunted postprandial PYY response. Clin. Endocrinol. (Oxf) 66(2), 198, (2007).
65. Leonetti F., Silecchia G., Iacobellis G., Ribaudo M.C., Zappaterreno A., Tiberti C., Iannucci C.V., Perrotta N. et al.: Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J. Clin. Endocrinol. Metab. 88(99), 4227, (2003).
66. Cowley M.A., Smith R.G., Diano S., Tschop M., Pronchuk N., Grove K.L., Strasburger C.J., Bidlingmaier M. et al.: The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37(4), 649, (2003).
67. Egido E.M., Rodriguez-Gallardo J., Silvestre R.A., Marco J.: Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. Eur. J. Endocrinol. 146(2), 241, (2002).
68. Date Y., Nakazato M., Hashiguchi S., Dezaki K., Mondal M.S., Hosoda H., Kojima M., Kangawa K. et al.: Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 51(1), 124, (2002).
69. Lee H.M., Wang G., Englander E.W., Kojima M., Greeley G.H.: Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 143(1), 185, (2002).
70. Adeghate E, Ponery AS.: Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. J. Neuroendocrinol. 2002; 14(7): 555-560.
71. Broglio F., Arvat E., Benso A., Gottero C., Muccioli G., Papotti M., van der Lely A.J., Deghenghi R. et al.: Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J. Clin. Endocrinol. Metab. 86(10), 5083, (2001).
72. Broglio F., Benso A., Castiglioni C., Gottero C., Prodam F., Destefanis S., Gauna C., van der Lely A.J. et al.: The endocrine response to ghrelin as a function of gender in human young and elderly subjects. J. Clin. Endocrinol. Metab. 88(4), 1537, (2003).
73. Arosio M., Ronchi C.L., Gebbia C., Cappiello V., Beck-Peccoz P., Peracchi M.: Stimulatory effects of ghrelin on circulating somatostatin and pancreatic polypeptide levels. J. Clin. Endocrinol. Metab. 88(2), 701, (2003).
74. Tassone F., Broglio F., Destefanis S., Rovere S., Benso A., Gottero C., Prodam F., Rossetto R. et al.: Neuroendocrine and metabolic effects of acute ghrelin administration in human obesity. J. Clin. Endocrinol. Metab. 88(11), 5478, (2003).
75. Akamizu T., Takaya K., Irako T., Hosoda H., Teramukai S., Matsuyama A., Tada H., Miura K. et al.: Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur. J. Endocrinol. 150(4), 447, (2004).
76. Alvarez-Castro P., Isidro M.L., García-Buela J., Dieguez C., Casanueva F.F., Cordido F.: Effect of acute ghrelin administration on glycaemia and insulin levels in obese patients. Diabetes Obes. Metab. 8(5), 555, (2006).
77. 2+ signaling and insulin release in islet beta-cells: novel signal transduction of ghrelin. Diabetes 56(9), 2319, (2007).
78. Tritos N.A., Kissinger K.V., Manning W.J., Danias P.G.: Association between ghrelin and cardiovascular indexes in healthy obese and lean men. Clin. Endocrinol. 60(1), 60, (2004).
79. Nagaya N., Kojima M., Uematsu M., Yamagishi M., Hosoda H., Oya H., Hayashi Y., Kangawa K.: Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280(5), R1483, (2001).
80. King M.K., Gay D.M., Pan L.C., McElmurray J.H., Hendrick J.W., Pirie C., Morrison A., Ding C. et al.: Treatment with growth hormone secretagogues in a model of developing heart failure: Effects on ventricular and myocyte function. Circulation 103(2), 308, (2001).
81. Chang L., Ren Y., Liu X.G., Yang J., Geng B., Weintraub N.L., Tang C.: Protective effect of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J. Cardiovasc. Pharmacol. 43(2), 165, (2004).
82. Broglio F., Guarracino F., Benso A., Gottero C., Prodam F., Granata R., Avogadri E., Muccioli G. et al.: Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. Eur. J. Pharmacol. 448(7), 193, (2002).
83. Makino Y., Hosoda H., Shibata K., Makino I., Kojima M., Kangawa K., Kawarabayashi T.: Alteration of plasma ghrelin levels associates with the blood pressure in pregnancy. Hypertension 39(3), 781, (2002).
84. Deboer M.D., Zhu X., Levasseur P.R., Inui A., Hu Z., Han G., Mitch W.E., Taylor J.E. et al.: Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 149(2), 827, (2008).
85. Alvarez-García O., García-López E., Rodríguez J., Gil-Peña H., Molinos I., Carbajo-Pérez E., Santos F.: Administration of ghrelin to young uraemic rats increases food intake transiently, stimulates growth hormone secretion and does not improve longitudinal growth. Nephrol. Dial. Transplant. 22(5), 1309, (2007).
86. Dornonville De la Cour C., Lindström E., Norlén P., Håkanson R.: Ghrelin stimulates gastric emptying but is without effect on acid secretion and gastric endocrine cells. Regul. Pept. 120(1-3), 23, (2004).
87. Isidro M.L., Cordido F.: Growth hormone secretagogues. Comb. Chem. High T. Scr. 9(3), 175, (2006).
88. Yang L., Morriello G., Pan Y., Nargund R.P., Barakat K., Prendergast K., Cheng K., Chan W.W. et al.: Tripeptide growth hormone secretagogues. Bioorg. Med. Chem. Lett. 8(7), 759, (1998).
89. Pihoker C., Middleton R., Reynolds G.A., Bowers C.Y., Badger T.M.: Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. J. Clin. Endocrinol. Metab. 80(10), 2987, (1995).
90. Mericq V., Cassorla F., Salazar T., Avila A., Iniguez G., Bowers C.Y., Merriam G.R.: Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J. Clin. Endocrinol. Metab. 83(7), 2355, (1998).
91. Laferrère B., Abraham C., Rusell C.D., Bowers C.Y.: Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J. Clin. Endocrinol. Metab. 90(2), 611, (2005).
92. Deghenghi R., Cananzi M.M., Torsello A., Battisti C., Muller E.E., Locatelli V.: GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 54(18), 1321, (1994).
93. Deghenghi R.: In Impervious peptides as GH secretagogues. Ghigo E., Boghem M., Casanueva F.F., Dieguez C., Eds. Elsevier Science B.V.: Amsterdam, pp. 19-24, (1999).
94. Guerlavais V., Boeglin D., Mousseaux D., Oiry C., Heitz A., Deghenghi R., Locatelli V., Torsello A. et al.: New active series of growth hormone secretagogues. J. Med. Chem. 46(7), 1191, (2003).
95. Broglio F., Boutignon F., Benso A., Gottero C., Prodam F., Arvat E., Ghe C., Catapano F. et al.: EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man. J. Endocrinol. Invest. 25(8), RC26, (2002).
96. Raun K., Hansen B.S., Johansen N.L., Thogersen H., Madsen K., Ankersen M., Andersen P.H.: Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol. 139(5), 552, (1998).
97. Hansen B.S., Raun K., Nielsen K.K., Johansen P.B., Hansen T.K., Peschke B., Lau J., Andersen P.H. et al.: Pharmacological characterisation of a new oral GH secretagogue. Eur. J. Endocrinol. 141(2), 180, (1999).
98. Svensson J., Monson J.P., Vetter T., Hansen T.K., Savine R., Kann P., Bex M., Reincke M. et al.: Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Clin. Endocrinol. (Oxf) 58(5), 572, (2003).
99. Fehrentz J.A., Martinez J., Boeglin D., Guerlavais V., Deghenghi R.: Growth hormone secretagogues: past, present and future. IDrugs, 5(8), 804, (2002).
100. DeVita R.J., Bochis R., Frontier A.J., Kotliar A., Fisher M.H., Schoen W.R., Wyvratt M.J., Cheng K. et al.: A potent, orally bioavailable benzazepinone growth hormone secretagogue. J. Med. Chem. 41(10), 1716. (1998).
101. Ye Z., Gao Y., Bakshi R.K., Chen M.H., Rohrer S.P., Feighner S.D., Pong S.S., Howard A.D. et al.: Modeling directed design and biological evaluation of quinazolinones as non-peptidic growth hormone secretagogues. Bioorg. Med. Chem. Lett. 10(1), 5, (2000).
102. Smith R.G., Cheng K., Schoen W.R., Pong S.S., Hickey G., Jacks T., Butler B., Chan W.W. et al.: A nonpeptidyl growth hormone secretagogue. Science 260(5114), 1640, (1993).
103. Patchett A.A., Nargund R.P., Tata J.R., Chen M.H., Barakat K.J., Johnston D.B., Cheng K., Chan W.W. et al.: Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc. Natl. Acad. Sci. USA 92(15), 7001, (1995)
104. Tokunaga T., Hume W.E., Umezome T., Okazaki K., Ueki Y., Kumagai K., Hourai S., Nagamine J. et al.: Oxindole derivatives as orally active potent growth hormone secretagogues. J. Med. Chem. 44(26), 4641, (2001).
105. Nagamine J., Nagata R., Seki H., Nomura-Akimaru N., Ueki Y., Kumagai K., Taiji M., Noguchi H.: Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686. J. Endocrinol. 171(3), 481, (2001).
106. Piccoli F., Degen L., MacLean C., Peter S., Baselgia L., Larsen F., Beglinger C., Drewe J.: Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J. Clin. Endocrinol. Metab. 92(5), 1814, (2007).
107. Holst B., Schwartz T.W.: Ghrelin receptor mutations-too little height and too much hunger. J. Clin. Invest. 116(3), 637, (2006).
108. Zorrilla E.P., Iwasaki S., Moss J.A., Chang J., Otsuji J., Inoue K., Meijler M.M., Janda K.D.: Vaccination against weight gain. Proc. Natl. Acad. Sci. USA 103(35), 13226, (2006).
109. Esler W.P., Rudolph J., Claus T.H., Tang W., Barucci N., Brown S.E., Bullock W., Daly M. et al.: Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 148(11), 5175, (2007).